IMUC: Immunotherapy On Multiple Fronts
In a study of 19 patients with glioblastoma, progression-free survival increased from 6 months to 19 months.
manish singh
ImmunoCellular Therapeutics at the 2010 OneMedForum
Manish Singh, President and CEO of ImmunoCellular Therapeutics, discusses his company with William Dawson of LifeTech Capital at the 2010 OneMedForum in San Francisco.
[OneMedForum] Immunocellular Therapeutics
The Los Angeles-based company discussed its recent clinical trials, including results from a Phase I study of ICT-107 to treat a deadly form of brain cancer called glioblastoma.